IMTX Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Zacks Investment Research - Mentions: JJSF ARMK TWST

Company News for Nov 18, 2025

18 days ago - By: Zacks Investment Research - Mentions: CVAC

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

18 days ago - By: https://immatics.com/

Immatics Announces Third Quarter 2025 Financial Results and Business Update

18 days ago - By: https://immatics.com/

Immatics Announces Third Quarter 2025 Financial Results and Business Update

21 days ago - By: Zacks Investment Research - Mentions: CGON

CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates

a month ago - By: https://immatics.com/

Immatics Appoints Amie Krause as Chief People Officer

2 months ago - By: https://immatics.com/

Immatics Appoints Venkat Ramanan as Chief Financial Officer

4 months ago - By: Zacks Investment Research - Mentions: ERJ BFIN

New Strong Sell Stocks for August 15th

22 days ago - By: Zacks Investment Research - Mentions: XLO

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

23 days ago - By: Zacks Investment Research - Mentions: IRD

Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates

23 days ago - By: https://immatics.com/

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

23 days ago - By: https://immatics.com/

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

a month ago - By: Zacks Investment Research - Mentions: GERN

Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: BEAM

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: https://immatics.com/

Immatics Appoints Amie Krause as Chief People Officer

2 months ago - By: https://immatics.com/

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

2 months ago - By: https://immatics.com/

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

2 months ago - By: Benzinga - Mentions: IVA YCBD IMAB NBTX ...

12 Health Care Stocks Moving In Friday's After-Market Session

2 months ago - By: Benzinga - Mentions: BOLT GOVX SCYX LPTX ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

2 months ago - By: https://immatics.com/

Immatics Appoints Venkat Ramanan as Chief Financial Officer

4 months ago - By: Zacks Investment Research - Mentions: DARE

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: https://immatics.com/

Immatics Announces Second Quarter 2025 Financial Results and Business Update

4 months ago - By: https://immatics.com/

Immatics Announces Second Quarter 2025 Financial Results and Business Update

4 months ago - By: Zacks Investment Research - Mentions: ARCT

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: DVAX

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

5 months ago - By: Yahoo Finance - Mentions: DB

Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)

6 months ago - By: https://immatics.com/

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

6 months ago - By: https://immatics.com/

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

7 months ago - By: https://immatics.com/

Immatics Announces First Quarter 2025 Financial Results and Business Update

7 months ago - By: https://immatics.com/

Immatics Announces First Quarter 2025 Financial Results and Business Update

7 months ago - By: Zacks Investment Research - Mentions: IBRX

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: CRDF

Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: DAWN

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates

8 months ago - By: https://immatics.com/

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

8 months ago - By: https://immatics.com/

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

8 months ago - By: Yahoo Finance - Mentions: PLTR AAPL USB

IMMATICS NV (IMTX) Stock News

IMTX Latest News, Press Relases and Analysis

Company News for Nov 18, 2025

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

Immatics Announces Third Quarter 2025 Financial Results and Business Update

Immatics Announces Third Quarter 2025 Financial Results and Business Update

CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates

Immatics Appoints Amie Krause as Chief People Officer

Immatics Appoints Venkat Ramanan as Chief Financial Officer

New Strong Sell Stocks for August 15th

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates

Immatics Appoints Amie Krause as Chief People Officer

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Immatics Appoints Venkat Ramanan as Chief Financial Officer

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

Immatics Announces Second Quarter 2025 Financial Results and Business Update

Immatics Announces Second Quarter 2025 Financial Results and Business Update

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

Immatics Announces First Quarter 2025 Financial Results and Business Update

Immatics Announces First Quarter 2025 Financial Results and Business Update

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds?